Brain appointed Peter Pitts as Executive Chairman and Chief Strategic Regulatory Officer, while Jacob Frenkel resigned as Chairman and transitioned to a consulting advisory role and Ibrahim B. Dagher resigned as EVP & Chief Medical Officer and moved to a consulting role.
| IndividualPeter PittsJacob Frenkel, Ph.D.Ibrahim B. Dagher, MD | RoleExecutive Chairman of the Board; Chief Strategic Regulatory OfficerChairman of the Board (resigned); transitioning to consultantExecutive Vice President & Chief Medical Officer (resigned); transitioning to consultant | Type of ChangeAppointedResigned (from Chairman and director); appointed consultantResigned; appointed consultant | Effective DateJuly 24, 2026July 24, 2026July 26, 2026 | ReasonNot disclosedTransition; resignation not due to any disagreement with the CompanyNot disclosed | Replacement InfoNot disclosedNot disclosedNot disclosed | Background DetailsBoard member; offer letter grants option to purchase 900,000 shares; no base salary or cash bonus; option vests 25% on July 24, 2027, remainder monthly over 3 yearsReceived RSUs for consulting: 100,000 RSUs; half vest Oct 24, 2026 and half vest Apr 24, 2027; acceleration of vesting of outstanding options/RSUs and extended post-termination exercise period approvedDagher Consulting Agreement for one year; while consulting, services treated as continued employment for equity awards; if compliant at term end, outstanding unvested equity will vest and post-termination exercise period extended | Board/Committee Role ChangesNot disclosedResigned as director and Chairman; will assist with transition of chairman duties as consultantNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.